» Articles » PMID: 12429993

Characterization of the CCK-C (cancer) Receptor in Human Pancreatic Cancer

Overview
Journal Int J Mol Med
Specialty Genetics
Date 2002 Nov 14
PMID 12429993
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The gastrointestinal peptides gastrin and cholecystokinin (CCK) stimulate growth of human pancreatic cancer by a receptor-mediated process. The purpose of this study was to investigate the molecular and functional characteristics of the receptor associated with peptide-induced pancreatic cancer proliferation. Utilizing total RNA from human pancreatic cancer cells a cDNA was cloned and sequenced by RT-PCR and rapid amplification of cDNA ends methodology. The molecular characteristics of the receptor cDNA were studied by Northern analysis and protein structure by Western analysis. An antibody raised against the novel receptor was utilized to investigate the role of the CCK-C receptor on pancreatic cancer cellular growth using in vitro technology. A spliced variant of the CCK-B receptor was identified which differed from the CCK-B receptor by the presence of intron 4. Northern analysis showed a transcript size of 3.2 Kb for the receptor mRNA in the human pancreatic cancer specimens, and Western blotting revealed binding to a 49 kDa protein in pancreatic tumors. Immunoreactivity was found in pancreatic cancer cells and tumors with localization in the cytoplasm. Treatment of BxPC-3 human cancer cells with the antibody resulted in growth inhibition. These data reveal the presence of a unique CCK receptor in human pancreatic cancer that functions in growth and is not present in normal human pancreas. The term CCK-C or 'cancer' receptor has been proposed to signify the relationship of this receptor to neoplasia.

Citing Articles

Metabolic Hormones Modulate Macrophage Inflammatory Responses.

Batty M, Chabrier G, Sheridan A, Gage M Cancers (Basel). 2021; 13(18).

PMID: 34572888 PMC: 8467249. DOI: 10.3390/cancers13184661.


Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting.

Verona M, Rubagotti S, Croci S, Sarpaki S, Borgna F, Tosato M Molecules. 2021; 26(4).

PMID: 33572353 PMC: 7916174. DOI: 10.3390/molecules26040918.


Identification of potent cholecystokinin-B receptor antagonists: synthesis, molecular modeling and anti-cancer activity against pancreatic cancer cells.

Kumari S, Chowdhury J, Sikka M, Verma P, Jha P, Mishra A Medchemcomm. 2018; 8(7):1561-1574.

PMID: 30108868 PMC: 6071963. DOI: 10.1039/c7md00171a.


Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor.

Nadella S, Burks J, Al-Sabban A, Inyang G, Wang J, Tucker R Am J Physiol Gastrointest Liver Physiol. 2018; 315(5):G699-G712.

PMID: 29927319 PMC: 6293257. DOI: 10.1152/ajpgi.00123.2018.


Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.

Smith J, Wang S, Nadella S, Jablonski S, Weiner L Cancer Immunol Immunother. 2017; 67(2):195-207.

PMID: 29043413 PMC: 5801048. DOI: 10.1007/s00262-017-2077-9.